Teva Gives OTCs “Major” Role In 2014 Outlook
This article was originally published in The Tan Sheet
Executive Summary
The Israeli firm reassures investors that the business is stable and is moving forward with strategic plans after the abrupt exit of its CEO. Teva’s OTC business will be a key driver of those plans, says interim CEO Eyal Desheh.